In fact, mesothelin-specific CD8+ T cell responses were observed earlier with Cy/GVAX+CRS-207 than Cy/GVAX only suggesting that the expected synergy of the prime boost approach was realized in terms of both efficacy and anti-tumor immune response. This evidence concerns the gene CD8A and neoplasm.